Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2521 to 2535 of 8221 results

  1. Vacuum Assisted Excision for the removal of breast lesions of uncertain malignant potential

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  2. Transarterial radio embolisation for osteosarcoma liver metastases

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  3. Cryoablation for Desmoid-type Fibromatosis

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  4. Subcutaneous olanzapine for treating schizophrenia [TSID12289]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  5. Menotrophin prefilled pen for treating anovulation or during controlled ovarian hyperstimulation [TSID12290]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  6. Monofocal intraocular lenses for cataract surgery (provisional title)

    In development Reference number: GID-HTE10090 Expected publication date: TBC

    Health technology evaluations
    In development

  7. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

    In development Reference number: GID-NG10434 Expected publication date:  02 December 2026

    NICE guideline
    In development

  8. Deuruxolitinib for treating severe alopecia areata ID6597

    In development Reference number: GID-TA11804 Expected publication date:  08 October 2026

    Technology appraisal guidance
    In development

  9. Kidney Cancer

    In development Reference number: GID-NG10398 Expected publication date:  19 March 2026

    NICE guideline
    In development

  10. Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy [ID6373]

    In development Reference number: GID-TA11439 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Maralixibat for treating cholestatic pruritus in Alagille syndrome [ID3941]

    In development Reference number: GID-TA10832 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Durvalumab with oleclumab or monalizumab for treating unresectable locally advanced non-small-cell lung cancer after platinum-based chemoradiotherapy [ID6626]

    Awaiting development Reference number: GID-TA11828 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Nipocalimab for treating generalised myasthenia gravis [ID6562]

    In development Reference number: GID-TA11492 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Dostarlimab for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency when systemic treatment is suitable [ID6660]

    Awaiting development Reference number: GID-TA11870 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Cemiplimab for adjuvant treatment of high-risk cutaneous squamous cell carcinoma after surgery and radiotherapy [ID6659]

    Awaiting development Reference number: GID-TA11869 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development